

Confirmation Report - Memory Send

Date & Time: Oct-05-2004 04:36pm
 Tel line : 650 857 0663
 Machine ID : COOLEY GODWARD LLP

Job number : 125
 Date & Time : Oct-05 04:35pm
 To : 15712730632
 Number of pages : 002
 Start time : Oct-05 04:35pm
 End time : Oct-05 04:36pm
 Pages sent : 002
 Status : OK

Job number : 125 ***** SEND SUCCESSFUL *****

Attorney Docket No. TLIC-030/01US
 Serial No. 09/748,665
 Page 1
 PATENT

Attorney Docket No. TLIC-030/01US

I hereby certify that this correspondence is being transmitted by facsimile addressed to Examiner Wang, Art Unit 1617, Facsimile Number 571-273-0632, at United States Patent and Trademark Office, Alexandria, VA 22313-1450 at 11:57AM on October 5, 2004.

By: Hanna M. Hahn
 Hanna Hahn

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Richard Sporterman et al.
 Serial No.: 09/748,665 Examiner: Wang, S.
 Confirmation No.: 8219 Art Unit: 1617
 Filed: December 21, 2000
 For: NONPEPTIDE INSULIN RECEPTOR AGONISTS

Mail Stop AF
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

LETTER TO EXAMINER

At the request of Examiner Wang during our conversation on October 1, 2004, a clean version of claim 27 of the previous amendment (without underlining or bracketing) is being provided herewith. The Examiner indicated he had sent out a new office action detailing the MPEP requirements for a new declaration. As the inventors are no longer at Tollik, Inc., a declaration will be provided as soon as the signatures from the inventors are obtained. This communication is being sent to fax number 571-273-0632 at the request of Examiner Wang.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. 1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment to Deposit Account No. (PA) 03-3117 or (RE) 50-1283.

Dated: 5 Oct. 2004
 Cooley Godward LLP
 ATTN: Patent Group
 Five Palo Alto Square
 3000 El Camino Real
 Palo Alto, CA 94306-2155
 Tel: (650) 843-5000 Fax: (650) 857-0663
 TMW/MHH

Respectfully submitted,
COOLEY GODWARD LLP

By: Tom M. Moran
 Tom M. Moran
 Reg. No. 26,314

000461 US/PA
 0013021.BOC

Attorney Docket No. TLIK-030/01US
 Serial No. 09/748,665
 Page 1
PATENT

Attorney Docket No. **TLIK-030/01US**

I hereby certify that this correspondence is being transmitted by facsimile addressed to Examiner Wang, Art Unit 1617, Facsimile Number 571-273-0632, at United States Patent and Trademark Office, Alexandria, VA 22313-1450 at 4:30PM on October 5, 2004.

By: Hanna Hacham
 Hanna Hacham

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Richard Sportsman et al.

Serial No.: 09/748,665

Examiner: Wang, S.

Confirmation No.: 8219

Art Unit: 1617

Filed: December 21, 2000

For: **NONPEPTIDE INSULIN RECEPTOR AGONISTS**

Mail Stop AF
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

LETTER TO EXAMINER

At the request of Examiner Wang during our conversation on October 1, 2004, a clean version of claim 27 of the previous amendment (without underlining and bracketing) is being provided herewith. The Examiner indicated he had sent out a new office action detailing the MPEP requirements for a new declaration. As the inventors are no longer at Telik, Inc., a declaration will be provided as soon as the signatures from the Inventors are obtained. This communication is being sent to fax number 571-273-0632 at the request of Examiner Wang.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. (PA) 03-3117 or (RE) 50-1283.

Dated: 5 Oct. 2004

Respectfully submitted,
COOLEY GODWARD LLP

Cooley Godward LLP
 ATTN: Patent Group
 Five Palo Alto Square
 3000 El Camino Real
 Palo Alto, CA 94306-2155
 Tel: (650) 843-5000 Fax: (650) 857-0663
 TMM\hh


By: Tom M. Moran
 Tom M. Moran
 Reg. No. 26,314

Attorney Doc No. TLIK-030/01US
Serial No. 09/748,665
Page 2

IN THE CLAIMS:

26. Cancelled

27. (amended) A method to lower blood glucose in a diabetic subject comprising administering to the subject a blood glucose-lowering effective amount of the compound of the formula



28. Cancelled